杯和lncRNAs:在癌症免疫力,预后和化疗敏感性方面的相互作用
Youcai Huang1, Lujing Meng2, Xiaoling Wang1
1School of Public Health, The First Dongguan AffiliateHospital, Guangdong Medical University, Dongguan, 523808, China.
Biochemical and biophysical research communications
|March 3, 2026
概括
铜受调节的细胞死亡途径cuproptosis与长非编码RNAs (lncRNAs) 相互作用,影响癌症免疫力和治疗反应. 针对这个"cuproptosis-lncRNA轴"为精密瘤学提供了一个新的策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 免疫学 免疫学 免疫学
背景情况:
- 铜,一种依赖铜的细胞死亡,以及长非编码RNA (lncRNAs) 是癌症的关键.
- 它们的相互作用被称为"cuproptosis-lncRNA轴",影响瘤免疫力,预后和治疗.
- 了解这一轴对于新的癌症治疗策略至关重要.
研究的目的:
- 在癌症生物学中提出和定义整合性的"cuproptosis-lncRNA轴".
- 根据其功能来分类与cuproptosis相关的lncRNAs.
- 探索针对精确瘤学这一轴的治疗潜力.
主要方法:
- 文献审查和概念综合.
- 与cuproptosis相关的lncRNAs的功能分类为原型 (ceRNA海绵,表观遗传调节器,信号枢纽).
- 阐明轴在铜平衡,线粒体应激和免疫调节中的作用.
主要成果:
- 杯 - lncRNA轴集成线粒体新陈代谢,细胞死亡和免疫反应.
- lncRNAs微调铜稳态和线粒体蛋白质毒性压力,影响恶性表型.
- 针对特定的lncRNA功能类可以克服免疫逃避和化学抵抗.
结论:
- cuproptosis-lncRNA轴为了解癌症进展和免疫逃避提供了一个新的框架.
- 针对这一轴,考虑到lncRNA的功能作用,是个性化癌症治疗的有希望的策略.
- 结合 cuproptosis 导向疗法与 lncRNA 向,有可能改善癌症治疗结果.
相关概念视频
02:39lncRNA - Long Non-coding RNAs
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA (lncRNA)...
02:53Adaptive Mechanisms in Cancer Cells
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:53Adaptive Mechanisms in Cancer Cells
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...